Schistosoma Mansoni Antigen Sm-p80: Prophylactic Efficacy using TLR4 Agonist Vaccine Adjuvant Glucopyranosyl Lipid A-Alum in Murine and Non-Human Primate Models

Zhang, Weidong; Ahmad, Gufran; Molehin, Adebayo J.; Torben, Workineh; Le, Liu; Kim, Eunjee; Lazarus, Samra; Siddiqui, Arif Jamal; Carter, Darrick; Siddiqui, Afzal A.

doi:10.1136/jim-2018-000786

Cited by 22 publications

(21 citation statements)

References 46 publications

(101 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rSm-p80 + GLA-Alum immunization regimen provided worm burden reduction by 33.33–53.13% and 38% in vaccinated mice and baboons, respectively. Strong Sm-p80 specific IgG, IgG1, IgG2a and IgM and a mix of TH cells response were observed in all immunized animals ( Zhang et al, 2018 ).…”

Section: Current Status Of Protein Vaccine Candidates Against mentioning

confidence: 95%

Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection

Eyayu

Zeleke

Worku

2020

Parasite Epidemiology and Control

View full text Add to dashboard Cite

Schistosomiasis is an acute and chronic tropical parasitic disease caused by blood dwelling worm of the genus Schistosoma. It is the most destructive disease globally and is a major cause of morbidity and mortality for developing countries. Three main species of schistosomes infect human beings from which S. mansoni is the most common and widespread. Over the last several decades, chemotherapy using praziquantel has been a commonly used strategy for the treatment and control of schistosomiasis. However, control programs focused exclusively on chemotherapy have been challenging because of the frequency and rapidity of reinfection and these programs were expensive. Thus, new schistosomiasis control strategies will be needed. Vaccination strategy would be an ideal tool for a significant and sustainable reduction in the transmission and disease burden of schistosomiasis. An effective anti schistosome vaccine would greatly contribute to decreasing schistosomiasis-associated morbidity via protective immune responses leading to reduced worm burdens and decreased egg production. Vaccine development is a long process that can take decades. There have been three candidate vaccines that have been produced by Good Manufacturing Procedure and entered human clinical trials for S. mansoni are Sm14, SmTSP-2, and Sm-p80. Other candidates that are in pre-clinical trials at various stages include paramyosin, Sm29, SmKI-1, and Sm23. Since the growth of several new technologies, including genomics, transcriptomics, microarrays, immunomic profiling, and proteomics, have helped in the identification of promising new target schistosome antigens. Therefore, this review considers the present status of protein vaccine candidates against Schistosoma mansoni and provides some insight on prospects vaccine design and discovery.

show abstract

Section: Current Status Of Protein Vaccine Candidates Against mentioning

confidence: 95%

Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection

Eyayu

Zeleke

Worku

2020

Parasite Epidemiology and Control

View full text Add to dashboard Cite

show abstract

“…Immunomodulation is usually defined as modulation of the immune system, and this can be done by any chemical agent that modifies the immune response or the functioning of the immune system via the stimulation of antibody formation or the inhibition of white blood cell activity [93]. Cordycepin has been reported to stimulate cytokine release of resting peripheral blood mononuclear cells (PBMCs) as well as influence PBMCs proliferation and transcription factors in a human acute monocytic leukemia cell line (THP-1).…”

Section: Cordycepin and Immunomodulatory Effectsmentioning

confidence: 99%

Cordycepin for Health and Wellbeing: A Potent Bioactive Metabolite of an Entomopathogenic Medicinal Fungus Cordyceps with Its Nutraceutical and Therapeutic Potential

et al. 2020

View full text Add to dashboard Cite

Cordyceps is a rare naturally occurring entomopathogenic fungus usually found at high altitudes on the Himalayan plateau and a well-known medicinal mushroom in traditional Chinese medicine. Cordyceps contains various bioactive components, out of which, cordycepin is considered most vital, due to its utmost therapeutic as well as nutraceutical potential. Moreover, the structure similarity of cordycepin with adenosine makes it an important bioactive component, with difference of only hydroxyl group, lacking in the 3′ position of its ribose moiety. Cordycepin is known for various nutraceutical and therapeutic potential, such as anti-diabetic, anti-hyperlipidemia, anti-fungal, anti-inflammatory, immunomodulatory, antioxidant, anti-aging, anticancer, antiviral, hepato-protective, hypo-sexuality, cardiovascular diseases, antimalarial, anti-osteoporotic, anti-arthritic, cosmeceutical etc. which makes it a most valuable medicinal mushroom for helping in maintaining good health. In this review, effort has been made to bring altogether the possible wide range of cordycepin’s nutraceutical potential along with its pharmacological actions and possible mechanism. Additionally, it also summarizes the details of cordycepin based nutraceuticals predominantly available in the market with expected global value. Moreover, this review will attract the attention of food scientists, nutritionists, pharmaceutical and food industries to improve the use of bioactive molecule cordycepin for nutraceutical purposes with commercialization to aid and promote healthy lifestyle, wellness and wellbeing.

show abstract

“…Several studies have demonstrated that IL-21 is induced at both the mRNA and protein levels during natural infections with several species of schistosomes in humans and in murine models of schistosomiasis (Milner et al, 2010; Bourke et al, 2013; Zhang Y. et al, 2016), as well as following vaccination with schistosome-derived peptides (Zhang et al, 2013, 2018; Bourke et al, 2014; Fairfax et al, 2015). Ileal lamina propria lymphocytes-(LPLs) and axillary lymph node-derived T cells and non-T cell subsets from uninfected rhesus macaques ( Macaca mulatta ) secreted high levels of IL-21 in a recall assay in response to S. mansoni (Sm) egg antigen (SmEA) and worm antigen (SmWA) preparations ex vivo (Torben et al, 2017).…”

Section: Helminth Parasitesmentioning

confidence: 99%

Interleukin (IL)-21 in Inflammation and Immunity During Parasitic Diseases

Solaymani-Mohammadi

Eckmann

Singer

2019

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Parasitic diseases cause significant morbidity and mortality in the developing and underdeveloped countries. No efficacious vaccines are available against most parasitic diseases and there is a critical need for developing novel vaccine strategies for care. IL-21 is a pleiotropic cytokine whose functions in protection and immunopathology during parasitic diseases have been explored in limited ways. IL-21 and its cognate receptor, IL-21R, are highly expressed in parasitized organs of infected humans as well in murine models of the human parasitic diseases. Prior studies have indicated the ability of the IL-21/IL-21R signaling axis to regulate the effector functions (e.g., cytokine production) of T cell subsets by enhancing the expression of T-bet and STAT4 in human T cells, resulting in an augmented production of IFN-γ. Mice deficient for either IL-21 (Il21−/−) or IL-21R (Il21r−/−) showed significantly reduced inflammatory responses following parasitic infections as compared with their WT counterparts. Targeting the IL-21/IL-21R signaling axis may provide a novel approach for the development of new therapeutic agents for the prevention of parasite-induced immunopathology and tissue destruction.

show abstract

Schistosoma Mansoni Antigen Sm-p80: Prophylactic Efficacy using TLR4 Agonist Vaccine Adjuvant Glucopyranosyl Lipid A-Alum in Murine and Non-Human Primate Models

Cited by 22 publications

References 46 publications

Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection

Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection

Cordycepin for Health and Wellbeing: A Potent Bioactive Metabolite of an Entomopathogenic Medicinal Fungus Cordyceps with Its Nutraceutical and Therapeutic Potential

Interleukin (IL)-21 in Inflammation and Immunity During Parasitic Diseases

Contact Info

Product

Resources

About